The use of medical-grade cannabis in patients non-responders to Nabiximols

J Neurol Sci. 2016 Sep 15:368:349-51. doi: 10.1016/j.jns.2016.07.059. Epub 2016 Jul 26.

Authors

Francesco Saccà¹, Chiara Pane², Antonio Carotenuto², Marco Massarelli², Roberta Lanzillo², Ettore Brunello Florio³, Vincenzo Brescia Morra²

Affiliations

¹ Federico II University, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Naples, Italy. Electronic address: francesco.sacca@unina.it.
² Federico II University, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Naples, Italy.
³ Farmacia Florio Dr. Ettore SNC, Naples, Italy.

PMID: 27538663
DOI: 10.1016/j.jns.2016.07.059

No abstract available

Keywords: Bedrocan; Cannabis; Nabiximols; Sativex; THC, Spasticity.

Publication types

Letter

MeSH terms

Adult
Cannabidiol / therapeutic use*
Dronabinol / therapeutic use*
Drug Combinations
Female
Humans
Male
Medical Marijuana / therapeutic use*
Middle Aged
Multiple Sclerosis / complications
Multiple Sclerosis / drug therapy*
Muscle Spasticity / drug therapy*
Muscle Spasticity / etiology
Retrospective Studies
Treatment Outcome

Substances

Drug Combinations
Medical Marijuana
Cannabidiol
Dronabinol
nabiximols